We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Demonstrates Rapid Immunofluorescence Quantitative Analyzers for POC Testing

By LabMedica International staff writers
Posted on 25 Jul 2023

Getein Biotech, Inc. More...

(Nanjing, China) is showcasing its latest innovations at AACC 2023 including its benchtop immunofluorescence and hematology analyzers as well as its handheld POCT analyzers.

At AACC 2023, Getein is demonstrating the Metis 600 integrated system that provides a suitable solution for immunofluorescence and hematology testing to low-volume laboratories. The combination of immunofluorescence and hematology methodologies in a single system allows for more comprehensive test items to be offered. Metis 600 improves laboratory efficiency through the highest level of automation and accelerates turnaround time for high-volume sample testing. Also on display is the MAGICL 6000 chemiluminescence immunoassay analyzer, a compact and innovative system offering an optimal choice for mid to high-workflow laboratories that need a one-step chemiluminescence solution. Highly productive and compact, this instrument enables fully automated operation and provides the fastest testing speed of any device of its size.

In addition, the company is demonstrating the Getein 1160 immunofluorescence quantitative analyzer - a multi-channel POCT analyzer with four incubation channels and one emergency test channel. It also has a constant test environment with 32℃ to ensure more accurate test results, making it ideal for applications in emergency, critical care (ICU, CCU), outpatient, cardiology, inpatient wards, clinical laboratories, etc. Alongside this, the company is demonstrating the Getein 1100 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnostics of laboratory and point-of-care testing. In addition, Getein is showcasing the CM-400 fully automated clinical chemistry analyzer that is intended to quantitatively analyze chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples, offering constant throughput of 400 T/h.

Related Links:
Getein Biotech, Inc. 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.